These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Is scleroderma a vasculopathy? Fleming JN; Nash RA; Mahoney WM; Schwartz SM Curr Rheumatol Rep; 2009 Apr; 11(2):103-10. PubMed ID: 19296882 [TBL] [Abstract][Full Text] [Related]
4. Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets. Gabrielli A; Svegliati S; Moroncini G; Luchetti M; Tonnini C; Avvedimento EV Autoimmun Rev; 2007 Dec; 7(2):121-6. PubMed ID: 18035321 [TBL] [Abstract][Full Text] [Related]
5. A radical proposal for the pathogenesis of scleroderma. Murrell DF J Am Acad Dermatol; 1993 Jan; 28(1):78-85. PubMed ID: 8425975 [TBL] [Abstract][Full Text] [Related]
6. Type I IFNs Regulate Inflammation, Vasculopathy, and Fibrosis in Chronic Cutaneous Graft-versus-Host Disease. Delaney TA; Morehouse C; Brohawn PZ; Groves C; Colonna M; Yao Y; Sanjuan M; Coyle AJ J Immunol; 2016 Jul; 197(1):42-50. PubMed ID: 27226090 [TBL] [Abstract][Full Text] [Related]
8. Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course. Becker MO; Riemekasten G Expert Rev Clin Immunol; 2016; 12(2):115-35. PubMed ID: 26558747 [TBL] [Abstract][Full Text] [Related]
9. Regulator of G-protein signaling 5 regulates the shift from perivascular to parenchymal pericytes in the chronic phase after stroke. Roth M; Gaceb A; Enström A; Padel T; Genové G; Özen I; Paul G FASEB J; 2019 Aug; 33(8):8990-8998. PubMed ID: 31039042 [TBL] [Abstract][Full Text] [Related]
10. Formyl Peptide Receptor 2 Activation Ameliorates Dermal Fibrosis and Inflammation in Bleomycin-Induced Scleroderma. Park GT; Kwon YW; Lee TW; Kwon SG; Ko HC; Kim MB; Kim JH Front Immunol; 2019; 10():2095. PubMed ID: 31552041 [TBL] [Abstract][Full Text] [Related]
11. Immunophenotypical analysis of myofibroblasts and mesenchymal cells in the bleomycin-induced rat scleroderma, with particular reference to their origin. Juniantito V; Izawa T; Yuasa T; Ichikawa C; Tanaka M; Kuwamura M; Yamate J Exp Toxicol Pathol; 2013 Jul; 65(5):567-77. PubMed ID: 22749686 [TBL] [Abstract][Full Text] [Related]
12. Scleroderma: from pathophysiology to novel therapeutic approaches. Hunzelmann N; Krieg T Exp Dermatol; 2010 May; 19(5):393-400. PubMed ID: 20507361 [TBL] [Abstract][Full Text] [Related]
13. Regulator of G protein signaling 5: a new player in vascular remodeling. Manzur M; Ganss R Trends Cardiovasc Med; 2009 Jan; 19(1):26-30. PubMed ID: 19467451 [TBL] [Abstract][Full Text] [Related]
14. Interleukin-4 and interleukin-13 as possible therapeutic targets in systemic sclerosis. Gasparini G; Cozzani E; Parodi A Cytokine; 2020 Jan; 125():154799. PubMed ID: 31400638 [TBL] [Abstract][Full Text] [Related]
15. Type I interferon dysregulation in Systemic Sclerosis. Skaug B; Assassi S Cytokine; 2020 Aug; 132():154635. PubMed ID: 30685202 [TBL] [Abstract][Full Text] [Related]
16. Keeping the Balance Right: Regulator of G Protein Signaling 5 in Vascular Physiology and Pathology. Ganss R Prog Mol Biol Transl Sci; 2015; 133():93-121. PubMed ID: 26123304 [TBL] [Abstract][Full Text] [Related]
17. An update on an immune system that goes awry in systemic sclerosis. van Bon L; Cossu M; Radstake TR Curr Opin Rheumatol; 2011 Nov; 23(6):505-10. PubMed ID: 21885976 [TBL] [Abstract][Full Text] [Related]
18. MxA is a clinically applicable biomarker for type I interferon activation in systemic lupus erythematosus and systemic sclerosis. Huijser E; van Helden-Meeuwsen CG; Groot N; Bodewes ILA; Wahadat MJ; Schreurs MWJ; van Daele PLA; Dalm VASH; van Laar JAM; van Hagen PM; Waris M; Kamphuis S; Versnel MA Rheumatology (Oxford); 2019 Jul; 58(7):1302-1303. PubMed ID: 30879072 [No Abstract] [Full Text] [Related]
19. Matrix Stiffness: the Conductor of Organ Fibrosis. Santos A; Lagares D Curr Rheumatol Rep; 2018 Jan; 20(1):2. PubMed ID: 29349703 [TBL] [Abstract][Full Text] [Related]
20. TBK1: A key regulator and potential treatment target for interferon positive Sjögren's syndrome, systemic lupus erythematosus and systemic sclerosis. Bodewes ILA; Huijser E; van Helden-Meeuwsen CG; Tas L; Huizinga R; Dalm VASH; van Hagen PM; Groot N; Kamphuis S; van Daele PLA; Versnel MA J Autoimmun; 2018 Jul; 91():97-102. PubMed ID: 29673738 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]